Stock AGEN AGENUS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Agenus Inc.

Equities

AGEN

US00847G8042

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 19:19:55 29/04/2024 BST 		5-day change 1st Jan Change
13.22 USD +13.13% Intraday chart for Agenus Inc. +126.69% -21.00%
04-12 Sector Update: Health Care Stocks Slipping Late Afternoon MT
04-12 Sector Update: Health Care MT

Business Summary

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Number of employees: 389

Sales per Business

USD in Million2022Weight2023Weight Delta
Non-cash Royalties
73.3 %
45 46.2 % 115 73.3 % +153.00%
License Fees and Milestones
16.0 %
5 5.1 % 25 16.0 % +400.00%
Deferred Research and Development
7.8 %
10 9.7 % 12 7.8 % +28.06%
Other
1.9 %
11 10.7 % 3 1.9 % -71.68%
Research and Development
0.9 %
2 1.7 % 1 0.9 % -14.38%
Clinical Product
0.1 %
1 0.8 % 0 0.1 % -84.78%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
98.1 %
88 89.3 % 153 98.1 % +75.22%
Rest of World
1.9 %
11 10.7 % 3 1.9 % -71.68%

Managers

Managers TitleAgeSince
Garo Armen CEO
 Chief Executive Officer 71 30/03/94
Christine Klaskin DFI
 Director of Finance/CFO 58 31/12/95
Craig Winter CTO
 Chief Tech/Sci/R&D Officer - -
Steven O’Day CTO
 Chief Tech/Sci/R&D Officer 63 31/12/20
Homa Yeganegi CTO
 Chief Tech/Sci/R&D Officer - 19/07/23
Zack Armen IRC
 Investor Relations Contact - 30/11/22
Tracy Mazza Clemente HRO
 Human Resources Officer - -
Eric Humes PRN
 Corporate Officer/Principal - 31/12/21
Alfred Dadson PRN
 Corporate Officer/Principal - 31/12/15
Robin Taylor PRN
 Corporate Officer/Principal - 19/07/23

Members of the board

Members of the board TitleAgeSince
Garo Armen CEO
 Chief Executive Officer 71 30/03/94
Ulf Arne Wiinberg BRD
 Director/Board Member 66 16/05/16
Susan Hirsch BRD
 Director/Board Member 71 07/10/20
Brian Corvese BRD
 Director/Board Member 67 07/03/07
Allison Jeynes-Ellis BRD
 Director/Board Member 58 06/11/18
Timothy Wright BRD
 Director/Board Member 66 06/12/06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 31,620 0 0 98.79 %
Stock B 1 20,946,003 20,692,218 ( 98.79 %) 0

Shareholders

NameEquities%Valuation
Deep Track Capital LP
7.566 %
31,697,539 7.566 % 18 M $
Deep Track Capital LP
7.566 %
31,697,539 7.566 % 18 M $
The Vanguard Group, Inc.
7.225 %
30,266,890 7.225 % 18 M $
Vanguard Fiduciary Trust Co.
7.225 %
30,266,890 7.225 % 18 M $
BlackRock Advisors LLC
7.200 %
30,160,788 7.200 % 17 M $
Point72 Asset Management LP
6.748 %
28,268,500 6.748 % 16 M $
Sofinnova Investments, Inc.
3.737 %
15,656,234 3.737 % 9 M $
Artal Group SA
3.731 %
15,631,235 3.731 % 9 M $
Point72 Asset Management LP
2.861 %
11,985,200 2.861 % 7 M $
STATE STREET CORPORATION
2.072 %
8,680,267 2.072 % 5 M $
NameEquities%Valuation
Brad Kelley
100.00 %
31,620 100.00 % 18 340 $

Holdings

NameEquities%Valuation
MINK THERAPEUTICS, INC.
62.75%
 21,772,863 62.75% 19,769,760 $

Company contact information

Agenus, Inc.

3 Forbes Road

02421-7305, Lexington

+781 674 4400

http://www.agenusbio.com
address Agenus Inc.(AGEN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Agenus Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.69 USD
Average target price
88.75 USD
Spread / Average Target
+659.20%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AGENUS INC. Stock Agenus Inc.
-21.00% 245M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.45% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+11.87% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.04% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.66% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.65% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.90% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+9.19% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AGEN Stock
  4. Company Agenus Inc.